Client Overview
The client is a large pharmaceutical company with a strong presence in complex generics, including injectable products. The company sought expert support to engage more effectively with the US FDA on a challenging injectable program.
Client Background
Despite internal technical expertise, the client encountered repeated Regulatory uncertainties and development hurdles for a complex injectable intended as a generic. The absence of a well crafted FDA engagement strategy risked delays, additional studies, and potential setbacks.
Services in Scope
Strategy and planning for US FDA product development meetings.
Authoring and preparation of briefing materials and meeting packages.
Regulatory consultation on development plans and data expectations for complex generics.
Support in aligning internal development strategy with FDA feedback.
Challenges
Complexity of the injectable product and its development pathway as a generic.
Limited clarity on FDA expectations for data requirements and study designs.
Need to structure productive, outcome oriented product development meetings with the agency.
Solution
Freyr designed a targeted FDA interaction strategy focused on precise questions, robust briefing documentation, and alignment of scientific justifications with Regulatory precedents. The team helped the client translate technical challenges into Regulatory questions and positioned the development program for constructive FDA feedback.
1
Assessed the development status, identified key technical and Regulatory uncertainties, and framed them into focused questions for the FDA.
2
Prepared comprehensive briefing packages and background documents highlighting product complexity, development data, and proposed approaches.
3
Supported the client in conducting product development meetings, capturing and interpreting FDA feedback for integration into the development plan.
4
Helped refine the Regulatory and development strategy post meeting, incorporating agency recommendations to derisk future submissions.
Impact
- Achieved structured and productive FDA engagement, reducing ambiguity around development requirements.
- Optimized development plans, minimizing risk of additional cycles or major deficiencies at the submission stage.
Freyr, through strategic regulation and expert facilitation, turned scattered FDA interactions into a coherent engagement model for the client’s complex generic injectable. The client gained clearer expectations, a refined development plan, and confidence for submission, informing future programs.
